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Results: We found 10 RCTs including 1575 patients. Longer dura-
tions of chemotherapy prolonged PFS (HR 0.83, 95% CI 0.75 to 0.93, 
p=0.0007) but not OS (HR 0.96, 95%CI 0.87 to 1.05, p=0.3). The 
results were comparable among the different trials, designs and drugs 
(heterogeneity p>0.3) and were unaffected by excluding the 3 trials of 
lowest quality. AE were more frequent with longer durations of chemo-
therapy. QL was assessed in 5 trials with variable results. 
Conclusions: Continuing chemotherapy for more than 3 or 4 cycles 
delayed disease progression, increased adverse events, and may have 
impaired quality of life, but did not improve overall survival. These 
ﬁndings raise doubts about the value of continuing chemotherapy 
beyond 4 cycles in NSCLC.
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Background: S-1 is an oral anticancer drug combining tegafur, oxonic 
acid, and CDHP. We have conducted a phase II trial to evaluate the 
efﬁcacy and toxicity of irinotecan in combination with S-1 for patients 
with advanced NSCLC. 
Method: Chemotherapy-naïve pts with advanced stage (IIIB/IV) 
NSCLC, ECOG PS of 0-1, and adequate organ functions were treated 
with i.v. irinotecan 150 mg/m2 on day 1 and oral S-1 80 mg/m2/day on 
days 1 to 14 every 3 weeks. The primary objective of this study was to 
determine the objective response rate. With the target activity level of 
35% and the lowest response rate of interest set at 20%, 50 eligible pa-
tients were required with an 80% power to accept the hypothesis and a 
5% signiﬁcance level to reject the hypothesis. Allowing for a 10% loss 
to follow-up rate, a total of 55 patients were planned to enroll. 
Results: Fifty-six patients were enrolled between February 2006 and 
June 2006 and received a total of 255 treatment cycles (median 4; 
range, 1-12). No complete response and 16 partial responses were 
observed for an overall response rate of 28.6%. Twenty-four patients 
(42.9%) had stable disease and twelve patients (21.4%) had progress 
disease as best response. The tumor control rate (partial response + 
stable disease) was 71.4%. Survival data and detail toxicity proﬁles will 
be presented at the meeting. 
Conclusion: The combination of irinotecan/S-1 is well tolerated, can 
be used for outpatients, and is active for the treatment of advanced 
NSCLC. This treatment merits further comparison with other platinum-
based combinations.
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Background: Intravenous weekly NVB (NVBiv) and CDDP (NC) 
represents one of the reference treatments for advanced NSCLC. An 
oral formulation of NVB (NVBo) has been approved in NSCLC with 
similar efﬁcacy as NVBiv. GLOB3 compared, in histologically con-
ﬁrmed advanced NSCLC chemonaïve patients (age 18-75 years; KPS 
80-100%), NVBiv D1 and NVBo D8 versus DTX in a CDDP-based 
combination (DC) as time to treatment failure (TTF), overall response 
(OR), progression-free survival (PFS), overall survival (OS) and toler-
ance (NCI-CTC v2 criteria).
Methods: An estimated sample size of 350 patients (386 to accom-
modate an anticipated 10% loss of follow-up) was required (type I error 
5%, power 80%, two-sided Log-rank test adjusted on stage), assuming 
a median TTF NC/DC 3.8/2.8 months, and an accrual time 24 months. 
Patients randomly received: CDDP 80 mg/m2 with NVBiv 30 mg/m2 
D1 and NVBo 80 mg/m2 D8 every 3 weeks, after a 1st cycle at NVBiv 
25 mg/m2 D1 and NVBo 60 mg/m2 D8 (dose escalated in absence of 
grade 3/4 neutropenia), or CDDP 75 mg/m2 and DTX 75 mg/m2 D1 
every 3 weeks, for a maximum of 6 cycles in both arms.
Results: Between 09.02.2004 and 10.01.2006, 390 patients (NC/DC: 
194/196) were randomised and 381 (190/191) were treated. Disease 
extension at study entry (%): unresectable locoregional 20.5/15.2, 
metastatic 79.5/84.8, patients with ≥ 3 organs involved 45.3/40.8. 
Median age: 59.4/62.1 years. Male: 139/146. Squamous (%): 34.2/33.5, 
Adenocarcinoma 41.6/39.3. Mean number of cycles: NC 4.2 ± 1.8, DC 
4.4 ± 1.9. Median Relative DI (%): NVB 92, DTX 96.3. NVBiv and 
NVBo dose escalation at Cycle 2: 71%. Median TTF (months), ITT 
analysis (median follow-up 18 months) [95% CI]: NC 3.2 [NC 2.9-4.2], 
DC 4.1 [3.4-4.5] (p= 0.19). Overall Response (RECIST) [95% CI] (ITT 
after panel review): NC 27.4% [21.2-34.2], DC 27.2% [21.0-34.2]. Me-
dian PFS (months) [95% CI]: NC 4.9 [4.4-5.9], DC 5.0 [4.3-6.1] (p= 
0.98). Median OS (months) [95% CI]: NC 9.9 [8.6-11.6], DC 9.8 [8.8-
11.5] (p= 0.66). G 3/4 haematological toxicity (number of cycles: NC 
807, DC 845): neutropenia NC 23.3%; DC 28.2%; thrombopenia: NC 
0.9%, DC 0.1%; haemoglobin: NC 4.7%, DC 1.2%; febrile neutropenia 
(Pizzo’s deﬁnition, % patients): NC 10.5, DC 5.2. Non haematological 
toxicity (% of patients): G1/2 alopecia: NC 35.3%, DC 58.1%. G3/4 
fatigue: NC 5.8%, DC 6.3%. G3/4 diarrhoea: NC 2.1%, DC 5.8%. G3/4 
constipation: NC 0.5%, DC 1%. G3/4 sensory neuropathy: NC 0.5%, 
DC 0%.
Conclusions: NVB oral offers opportunities to optimise D1, D8 NC 
regimen. NVB and CDDP achieves similar efﬁcacy as DC in terms of 
TTF, OR, TTP and OS with similar and acceptable tolerance as front-
line chemotherapy for advanced NSCLC patients.
